Sociedad Americana de Hirudoterapia

Comparison of Screening Scores for Heparin- Induced Thrombocytopenia After Cardiopulmonary Bypass

Research article published in Journal of cardiothoracic and vascular anesthesia (2022)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportEnsayos clínicosCutler et al. · Journal of cardiothoracic and vascular anesthesia, 2022

Abstract

OBJECTIVES: To compare screening scores for heparin-induced thrombocytopenia (HIT) after cardiopulmonary bypass (CPB). DESIGN: Retrospective cohort study. SETTING: Cardiothoracic surgery units within a large tertiary healthcare facility from September 2010 to January 2020. PARTICIPANTS: All adult patients tested for heparin-induced platelet antibody (HIPA) within 2 weeks after surgery requiring CPB. INTERVENTIONS: Using data available to providers at the time HIPA were checked, the 4T's Score, a modified 4T's Score, and a score proposed by Lillo-Le Louet (LLL) et al. were calculated. A retrospective chart review was performed for each patient to determine actual presence of HIT, and screening scores were compared for accuracy. MEASUREMENTS AND MAIN RESULTS: Criteria for inclusion were met in 266 patients. Of these, 34 (12.8%) were high likelihood of HIT, 16 (6.0%), additional patients were clinically ambiguous, and 216 (81.2%) were high likelihood of alternative cause for thrombocytopenia. HIPA tests done before postoperative day 5 were not associated with any high-likelihood cases of HIT regardless of preoperative heparin exposure. Although traditional 4T's ≥4, modified 4T's ≥3, and LLL ≥2 had statistically similar sensitivity for predicting HIT, the modified 4T's and LLL had superior specificity (p < 0.001). CONCLUSIONS: Appropriate screening for HIT curbed inappropriate HIPA testing, and reduced the need for empirical treatment while awaiting confirmatory test results. Traditional 4T's was statistically inferior to both the LLL score and a modified version of the 4T's to screen for HIT within 2 weeks of CPB.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAdultAnticoagulantsBlood PlateletsCardiopulmonary BypassHeparinHumansRetrospective StudiesThrombocytopenia

Resumen

Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.

Por qué esto importa para la hirudoterapia

Esta cohorte retrospectiva (266 adultos evaluados para detectar anticuerpos plaquetarios inducidos por heparin dentro de las dos semanas posteriores a la circulación extracorpórea) comparó el puntaje 4T's, un 4T's modificado y el puntaje de Lillo-Le Louet para el cribado de la trombocitopenia inducida por heparin (HIT); el resumen informa que el 4T's tradicional fue estadísticamente inferior, mientras que el 4T's modificado y el LLL tuvieron una especificidad superior (p < 0.001), y que un cribado adecuado redujo las pruebas de anticuerpos innecesarias y el tratamiento empírico. Para la hirudoterapia esto es contextual más que directo: HIT es precisamente el escenario en el que un anticoagulante no basado en heparin es importante, y las moléculas derivadas de sanguijuelas como hirudin actúan de forma independiente al factor plaquetario 4, lo que enmarca por qué el secretoma de la sanguijuela medicinal se estudia como una alternativa de anticoagulación. Advertencia honesta: este estudio trata sobre herramientas de cribado de complicaciones por heparin en pacientes de cirugía cardíaca y no examina las sanguijuelas ni ninguna terapia derivada de sanguijuelas, por lo que informa el panorama de evidencia de anticoagulación circundante solo de manera indirecta.

Citación

Comparison of Screening Scores for Heparin- Induced Thrombocytopenia After Cardiopulmonary Bypass.

Cutler et al. · Journal of cardiothoracic and vascular anesthesia, 2022

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.